BioWorld Asia

Dec. 13, 2006

View Archived Issues

Blindness Gene Identified In Chickens Could Have Impact

Novexel Licenses Aminocandin From Indevus Pharmaceuticals

Belgium's ThromboGenics In Novel Biotech Deal With India

Trophos Announces Plans For ALS TRO19622 Phase II/III Trial

Actelion Shares On Rise As Actelion-1 Now In Phase III

Peptech Ponders Various Ways Of Spending £71.3M

Genfit To List Shares On Alternext Market In Paris

PanGenetics In Deals With Schering-Plough, LayLine

Other News To Note

Newron Raises CHF118.12M In Swiss Initial Public Offering

Shares in Newron Pharmaceuticals SpA opened on the Swiss Stock Exchange in Zurich at CHF58 (US$48.20) Tuesday, more than 5 percent above its initial public offering price of CHF55 per share. (BioWorld International) Read More

Pharminox, Schering-Plough Enter Deal Worth Up To $40M

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...